213 related articles for article (PubMed ID: 21797210)
1. Photocontrolled DNA binding of a receptor-targeted organometallic ruthenium(II) complex.
Barragán F; López-Senín P; Salassa L; Betanzos-Lara S; Habtemariam A; Moreno V; Sadler PJ; Marchán V
J Am Chem Soc; 2011 Sep; 133(35):14098-108. PubMed ID: 21797210
[TBL] [Abstract][Full Text] [Related]
2. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.
Chen H; Parkinson JA; Parsons S; Coxall RA; Gould RO; Sadler PJ
J Am Chem Soc; 2002 Mar; 124(12):3064-82. PubMed ID: 11902898
[TBL] [Abstract][Full Text] [Related]
3. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
4. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
5. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.
Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F
Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875
[TBL] [Abstract][Full Text] [Related]
6. Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.
Betanzos-Lara S; Novakova O; Deeth RJ; Pizarro AM; Clarkson GJ; Liskova B; Brabec V; Sadler PJ; Habtemariam A
J Biol Inorg Chem; 2012 Oct; 17(7):1033-51. PubMed ID: 22791215
[TBL] [Abstract][Full Text] [Related]
7. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
[TBL] [Abstract][Full Text] [Related]
8. Photocontrolled nucleobase binding to an organometallic Ru(II) arene complex.
Betanzos-Lara S; Salassa L; Habtemariam A; Sadler PJ
Chem Commun (Camb); 2009 Nov; (43):6622-4. PubMed ID: 19865670
[TBL] [Abstract][Full Text] [Related]
9. Chlorido-, aqua-, 9-ethylguanine- and 9-ethyladenine-adducts of cytotoxic ruthenium arene complexes containing O,O-chelating ligands.
Melchart M; Habtemariam A; Parsons S; Sadler PJ
J Inorg Biochem; 2007 Nov; 101(11-12):1903-12. PubMed ID: 17582501
[TBL] [Abstract][Full Text] [Related]
10. Competition between glutathione and DNA oligonucleotides for ruthenium(II) arene anticancer complexes.
Wang F; Xu J; Wu K; Weidt SK; Mackay CL; Langridge-Smith PR; Sadler PJ
Dalton Trans; 2013 Mar; 42(9):3188-95. PubMed ID: 23076358
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cancer cell growth by ruthenium(II) arene complexes.
Morris RE; Aird RE; Murdoch Pdel S; Chen H; Cummings J; Hughes ND; Parsons S; Parkin A; Boyd G; Jodrell DI; Sadler PJ
J Med Chem; 2001 Oct; 44(22):3616-21. PubMed ID: 11606126
[TBL] [Abstract][Full Text] [Related]
12. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells.
Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V
Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087
[TBL] [Abstract][Full Text] [Related]
13. Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.
Meier SM; Novak M; Kandioller W; Jakupec MA; Arion VB; Metzler-Nolte N; Keppler BK; Hartinger CG
Chemistry; 2013 Jul; 19(28):9297-307. PubMed ID: 23712572
[TBL] [Abstract][Full Text] [Related]
14. Anticancer activity and DNA binding of a bifunctional Ru(II) arene aqua-complex with the 2,4-diamino-6-(2-pyridyl)-1,3,5-triazine ligand.
Busto N; Valladolid J; Martínez-Alonso M; Lozano HJ; Jalón FA; Manzano BR; Rodríguez AM; Carrión MC; Biver T; Leal JM; Espino G; García B
Inorg Chem; 2013 Sep; 52(17):9962-74. PubMed ID: 23957818
[TBL] [Abstract][Full Text] [Related]
15. Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells.
Guo W; Zheng W; Luo Q; Li X; Zhao Y; Xiong S; Wang F
Inorg Chem; 2013 May; 52(9):5328-38. PubMed ID: 23586415
[TBL] [Abstract][Full Text] [Related]
16. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
17. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
18. Organometallic ruthenium anticancer complexes inhibit human glutathione-S-transferase π.
Lin Y; Huang Y; Zheng W; Wang F; Habtemariam A; Luo Q; Li X; Wu K; Sadler PJ; Xiong S
J Inorg Biochem; 2013 Nov; 128():77-84. PubMed ID: 23942162
[TBL] [Abstract][Full Text] [Related]
19. Binding of mismatch repair protein MutS to mispaired DNA adducts of intercalating ruthenium(II) arene complexes.
Castellano-Castillo M; Kostrhunova H; Marini V; Kasparkova J; Sadler PJ; Malinge JM; Brabec V
J Biol Inorg Chem; 2008 Aug; 13(6):993-9. PubMed ID: 18491151
[TBL] [Abstract][Full Text] [Related]
20. Understanding the interactions of diruthenium anticancer agents with amino acids.
Nazarov AA; Mendoza-Ferri MG; Hanif M; Keppler BK; Dyson PJ; Hartinger CG
J Biol Inorg Chem; 2018 Oct; 23(7):1159-1164. PubMed ID: 30046902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
